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Older adults, including those with long-term conditions (LTCs), are vulnerable to social isola-
tion. They are likely to have become more socially isolated during the Coronavirus Disease
2019 (COVID-19) pandemic, often due to advice to “shield” to protect them from infection.
This places them at particular risk of depression and loneliness. There is a need for brief
scalable psychosocial interventions to mitigate the psychological impacts of social isolation.
Behavioural activation (BA) is a credible candidate intervention, but a trial is needed.
Methods and findings
We undertook an external pilot parallel randomised trial (ISRCTN94091479) designed to
test recruitment, retention and engagement with, and the acceptability and preliminary
effects of the intervention. Participants aged�65 years with 2 or more LTCs were recruited
in primary care and randomised by computer and with concealed allocation between June
and October 2020. BA was offered to intervention participants (n = 47), and control partici-
pants received usual primary care (n = 49). Assessment of outcome was made blind to treat-
ment allocation. The primary outcome was depression severity (measured using the Patient
Health Questionnaire 9 (PHQ-9)). We also measured health-related quality of life (measured
by the Short Form (SF)-12v2 mental component scale (MCS) and physical component
scale (PCS)), anxiety (measured by the Generalised Anxiety Disorder 7 (GAD-7)), per-
ceived social and emotional loneliness (measured by the De Jong Gierveld Scale: 11-item
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loneliness scale). Outcome was measured at 1 and 3 months. The mean age of participants
was aged 74 years (standard deviation (SD) 5.5) and they were mostly White (n = 92,
95.8%), and approximately two-thirds of the sample were female (n = 59, 61.5%). Remote
recruitment was possible, and 45/47 (95.7%) randomised to the intervention completed 1 or
more sessions (median 6 sessions) out of 8. A total of 90 (93.8%) completed the 1-month
follow-up, and 86 (89.6%) completed the 3-month follow-up, with similar rates for control (1
month: 45/49 and 3 months 44/49) and intervention (1 month: 45/47and 3 months: 42/47)
follow-up. Between-group comparisons were made using a confidence interval (CI)
approach, and by adjusting for the covariate of interest at baseline. At 1 month (the primary
clinical outcome point), the median number of completed sessions for people receiving the
BA intervention was 3, and almost all participants were still receiving the BA intervention.
The between-group comparison for the primary clinical outcome at 1 month was an adjusted
between-group mean difference of −0.50 PHQ-9 points (95% CI −2.01 to 1.01), but only a
small number of participants had completed the intervention at this point. At 3 months, the
PHQ-9 adjusted mean difference (AMD) was 0.19 (95% CI −1.36 to 1.75). When we exam-
ined loneliness, the adjusted between-group difference in the De Jong Gierveld Loneliness
Scale at 1 month was 0.28 (95% CI −0.51 to 1.06) and at 3 months −0.87 (95% CI −1.56 to
−0.18), suggesting evidence of benefit of the intervention at this time point. For anxiety, the
GAD adjusted between-group difference at 1 month was 0.20 (−1.33, 1.73) and at 3 months
0.31 (−1.08, 1.70). For the SF-12 (physical component score), the adjusted between-group
difference at 1 month was 0.34 (−4.17, 4.85) and at 3 months 0.11 (−4.46, 4.67). For the SF-
12 (mental component score), the adjusted between-group difference at 1 month was 1.91
(−2.64, 5.15) and at 3 months 1.26 (−2.64, 5.15). Participants who withdrew had minimal
depressive symptoms at entry. There were no adverse events. The Behavioural Activation
in Social Isolation (BASIL) study had 2 main limitations. First, we found that the intervention
was still being delivered at the prespecified primary outcome point, and this fed into the
design of the main trial where a primary outcome of 3 months is now collected. Second, this
was a pilot trial and was not designed to test between-group differences with high levels of
statistical power. Type 2 errors are likely to have occurred, and a larger trial is now underway
to test for robust effects and replicate signals of effectiveness in important secondary out-
comes such as loneliness.
Conclusions
In this study, we observed that BA is a credible intervention to mitigate the psychological
impacts of COVID-19 isolation for older adults. We demonstrated that it is feasible to under-
take a trial of BA. The intervention can be delivered remotely and at scale, but should be
reserved for older adults with evidence of depressive symptoms. The significant reduction in
loneliness is unlikely to be a chance finding, and replication will be explored in a fully pow-
ered randomised controlled trial (RCT).
Trial registration
ISRCTN94091479.
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Author summary
Why was this study done?
• Older people with long-term conditions (LTCs) have been impacted by the Coronavirus
Disease 2019 (COVID-19) pandemic and its restrictions. They are at risk of social isola-
tion and, in turn, this could cause depression and loneliness, which are bad for health.
Psychological approaches, such as behavioural activation (BA), could be helpful.
• A fair test is needed to demonstrate if BA can prevent the onset of depression and loneli-
ness, but before we can do this, it is important to test this out in a smaller scale study.
What did the researchers do and find?
• We designed a brief telephone-delivered intervention based on sound psychological
principles known as BA. Here, we present the result of a pilot trial.
• We demonstrate that the intervention is acceptable to older people who are socially iso-
lated as a consequence of the pandemic. We tested whether it is possible to collect
important outcomes in the short term.
• There was some preliminary evidence that levels of loneliness were reduced at 3 months
when BA is offered.
What do these findings mean?
• This was a smaller scale pilot study, and our procedures worked well.
• If BA is shown to work, then this will be useful for policymakers in offering support to
people who are socially isolated.
• This will also be useful once the COVID-19 pandemic has passed, since loneliness is
common in older populations, and effective scalable solutions will be needed even after
COVID-19.
• The Behavioural Activation in Social Isolation (BASIL) pilot trial was not designed to
test differences in outcomes between the 2 groups. We will now test this in a much
larger study.
Introduction
In March 2020, a pandemic due to a new virus, the Severe Acute Respiratory Syndrome Coro-
navirus 2 (SARS-CoV-2), was declared. The first wave reached the United Kingdom within a
short period of time, and, in March 2020, the UK governments (including devolved nations)
administered a national stay-at-home order (“lockdown”), which included instructions for
people to follow physical social distancing and self-isolation guidelines and recommendations
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for strict isolation (“shielding”) for the most vulnerable (such as those with long-term condi-
tions (LTCs) and older people) in order to protect their own and others’ health and to avoid a
sudden increase in demand on the National Health Service (NHS). Shielding orders were
eased in the second half of 2020 but were reintroduced in January 2021 as part of a further
lockdown in response to subsequent Coronavirus Disease 2019 (COVID-19) waves. Many
people with LTCs have remained avoidant of social contact in order to protect themselves
from COVID-19 throughout the pandemic, irrespective of official guidance [1]. Similar rec-
ommendations and restrictions were also set in place in many healthcare systems around the
world.
The mental health of the population has deteriorated during COVID-19 [2]. Many report
social isolation, and the incidence of depression and anxiety has increased for older people and
those with medical vulnerabilities [3]. A plausible mechanism for this is that COVID-19
restrictions have led to disruption of daily routine, loss of social contact and heightened isola-
tion, and increased loneliness, which are each powerful precipitants of mental ill health [4].
Anticipating these behavioural and psychological consequences, a rapid review published in
The Lancet [5] highlighted the detrimental impacts on mental health of quarantine, but offered
limited advice on how this could be mitigated.
Social isolation, social disconnectedness, perceived isolation, and loneliness are known to
be linked to common mental health problems, such as depression in older people [4,6]. The
impairments in quality of life associated with depression are comparable to those of major
physical illness [7]. Loneliness is a risk factor for depression and is also known to be detrimen-
tal to physical health and life expectancy [8,9].
Loneliness is not an inevitable consequence of social isolation, and strategies to prevent or
mitigate loneliness were recognised as a population priority even before COVID-19 [10,11].
There are a number of promising interventions that focus on using social networks [12] or
adapting the strategies central to cognitive behavioural therapy [13]. It is recognised that strat-
egies that, for instance, maintain social connectedness could be important in ensuring the pop-
ulation mental health of older people [14], particularly during the pandemic [4] and in the
planning for post-pandemic recovery [15]. If a brief effective intervention for depression and
loneliness could be delivered at distance (such as via telephone) and at scale, then this would
lead to significant benefits to the NHS and society. This could potentially mitigate the immedi-
ate and longer lasting psychological impacts of COVID-19 on vulnerable populations, includ-
ing older people and those with LTCs [16].
Our research collaborative has previously developed, with input from older adults and car-
ers, a credible intervention that can potentially meet these needs in populations of older people
[17], and we have evaluated this in older populations with high rates of multiple LTCs [18,19].
Behavioural activation (BA) is a practical treatment that explores how physical inactivity and
low mood are linked and result in a reduction of valued activity [20]. Within BA, the therapist
and patient work together to develop a collaborative treatment plan that seeks to reinstate (or
replace, if former activities are no longer possible) behaviours that connect people to sources
of positive reinforcement (meaningful activity), including social connectedness. However, this
has not yet been tested in a large-scale clinical trial or in the context of the COVID-19 pan-
demic where social isolation is more prevalent. Small-scale trials of BA delivered to socially iso-
lated older people have produced encouraging preliminary results [21], but there is not yet
sufficient research evidence to support whole-scale adoption or to inform the population
response to COVID-19.
Along with many researchers working in the field of mental health, we were keen to use our
existing research expertise and research capacity to help mitigate the impact of the COVID-19
pandemic. We therefore adapted our previous and ongoing work programme in early 2020 to
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answer the following question: “Can we prevent or ameliorate depression and loneliness in
older people with long-term conditions during isolation?”.
In this paper, we present the rationale and results of a pilot randomised controlled trial
(RCT) of manualised BA, adapted specifically to be delivered at scale and remotely (via the
telephone or video call) for older adults who may have become socially isolated as a conse-
quence of COVID-19. To the best of our knowledge, this is the first study to use behavioural
approaches to prevent loneliness and depression in the COVID-19 pandemic. In this pilot
RCT, we sought to assess the feasibility of recruiting and randomising participants to a trial of
BA, of delivering the intervention, and of retaining participants in the trial. The primary clini-
cal outcome was depression severity, as measured by the Patient Health Questionnaire 9
(PHQ-9), at 1 month post-randomisation; secondary clinical outcomes were health-related
quality of life, anxiety, and perceived social and emotional loneliness.
Methods
Study design and participants
The Behavioural Activation in Social Isolation (BASIL) study is an external pilot RCT [22] and
includes a concurrent qualitative study. The BASIL pilot is designed to provide key informa-
tion on methods of recruitment, intervention uptake, retention, experience of the BA interven-
tion for our target population, and acceptability of the intervention and training for
intervention practitioners (hereafter BASIL support workers (BSWs)).
The COVID-19 responsive BASIL trials programme is supported by the National Institute
for Health Research (NIHR) under grant RP-PG-0217-20006 and was adopted by the NIHR
Urgent Public Health programme on May 28, 2020 [23]. The protocol for the BASIL pilot
study was preregistered (ISRCTN94091479) on June 9, 2020, and recruitment took place
between June 23 and October 15, 2020 (18 weeks in total). Older adults at risk of loneliness
and depression as a consequence of social isolation under COVID-19 restrictions were
recruited from primary care registers in the North East of England. They were randomised to
receive either usual primary care from their general practice or BA intervention in addition to
usual care (see below for full description of usual care and BA intervention).
• Inclusion criteria: Older adults (65 years or over) with 2 or more physical LTCs. The prag-
matic definition and type of LTCs mirror that applied in primary care in the UK [24], and
we focused on common LTCs experienced by older people (asthma/chronic obstructive pul-
monary disease (COPD), diabetes, hypertension/coronary heart disease, and stroke) accord-
ing to the primary care Quality and Outcomes Framework (QOF) [25], but also included
conditions such as musculoskeletal problems and chronic pain. Participants included those
subject to Government guidelines regarding COVID-19 self-isolation, social distancing, and
shielding as relevant to their health conditions and age (although this was not a requirement
and these requirements changed during the study period).
• Exclusion criteria: Older adults who have cognitive impairment, bipolar disorder/psycho-
sis/psychotic symptoms, alcohol or drug dependence, in the palliative phase of illness, have
active suicidal ideation, are currently receiving psychological therapy, or are unable to speak
or understand English.
Potentially eligible patients were contacted by telephone by staff working with the general
practices. Those patients who expressed an interest in the study during this initial telephone
contact provided their verbal “permission to contact” for a member of the study team to
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contact them by telephone to discuss the study and determine eligibility. Interested patients
could also complete an online consent form or contact the study team directly.
Randomisation, concealment of allocation, and masking
After consent, eligible participants completed a baseline questionnaire over the telephone with
a study researcher. Consent was obtained, either in written form or via verbal consent
[recorded] over the telephone. Participants were then randomised and informed of their
group allocation (intervention or usual care with signposting). Participants were allocated in a
1:1 ratio using simple randomisation without stratification. Treatment allocation was con-
cealed from study researchers at the point of recruitment using an automated computer data
entry system, administered remotely by the York Trials Unit and using a computer-generated
code. Owing to the nature of the intervention, none of the participants, general practices,
study clinicians, or BSWs could be blinded to treatment allocation. General practitioners
(GPs) were informed by letter of participant treatment allocation. Outcome assessment was by
self-report, and study researchers facilitating the telephone-based outcome assessment were
blind to treatment allocation.
Intervention (BA)
The intervention (BA within a collaborative care framework) has been described elsewhere
[18] and was adapted for the purposes of the BASIL trial. Within the BASIL BA intervention,
the therapist (BSW) and participant worked together to develop a collaborative treatment plan
that sought to reinstate (or replace, if former activities were no longer possible because of social
isolation and/or LTCs) behaviours that connect them to sources of positive reinforcement (val-
ued activity). BA has the potential to address depression and loneliness in the presence of
social isolation in this way [17,26] and the simplicity of BA made it suitable for delivery in the
context of COVID-19.
Intervention participants were offered up to 8 sessions over a 4- to 6-week period delivered
by trained BSWs, accompanied by participant materials. Participants in the intervention group
were provided with a BASIL BA workbook. This booklet was modified to take account of gov-
ernment guidance regarding the need for social isolation/physical distancing and enforced iso-
lation for those people most at risk (“extremely vulnerable” people). For example, the BASIL
booklet discussed ways to replace activities that are no longer possible with ones that preserve
social distancing while helping participants stay connected with the activities and people
important to them; illustrative patient stories included in the booklet were modified to take
account of COVID-19 restrictions. Examples of replacement activities from the BASIL self-
help manual are presented in Box 1. BA acknowledged the disruption to people’s lives and
usual routines and encouraged the establishment of a balanced daily routine. The intervention
also recognised that participants may be worried about the current situation due to COVID-19
and suggested strategies to help cope.
All intervention sessions were delivered remotely via telephone or video call, according to
participant preference. The first session was scheduled to last approximately 1 hour, with sub-
sequent sessions lasting approximately 30 minutes.
Depression symptom monitoring at each intervention session was undertaken using a vali-
dated depression scale (the Depression Anxiety Stress Scales (DASS) [27]) with scores guiding
decision-making by BSWs and guided by supervision provided by clinical members of the
study team. Where risk or significant clinical deterioration was noted, the participant was sup-
ported to access more formal healthcare interventions (including mental health care) via their
GP. Where feasible and where considered appropriate and acceptable by the participant and
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BSW, the intervention was extended to include involvement of a participant’s informal care-
giver/significant other. Intervention participants continued to receive their usual care/treat-
ment (where this was feasible given COVID-19) alongside the BASIL intervention, and no
treatment was withheld.
Comparator (usual GP care)
Participants in the control group received usual care as provided by their current NHS and/or
third sector providers. In addition, control participants were “signposted” to reputable sources
of self-help and information, including advice on how to keep mentally and physically well.
Examples of such sources was the Public Health England’s (PHE) “Guidance for the public on
the mental health and wellbeing aspects of coronavirus (COVID-19)” [28] and Age UK [29].
Outcome measures
Demographic information was obtained at baseline and included age, sex, LTC type, socioeco-
nomic status, ethnicity, education, marital status, and number of children.
The primary objective for this pilot trial was to obtain estimates of key feasibility measures
including rates of recruitment, randomisation, retention, intervention delivery, and engagement.
Box 1. BASIL examples of replacement activities using functional
equivalence. See [17] for a description of the principles of BA and its
application in older people with LTCs
BA pays particular attention to the function the behaviour holds for an individual and
that reinforcement is determined functionally. An important consequence of this view is
the idea of functional equivalence. A specific form of a behaviour may have served a par-
ticular function for a person; however, that behaviour may no longer be possible due to
physical health problems or COVID-19 lockdown. In this situation, an aim of treatment
was to identify a functionally equivalent behaviour that is different and therefore still
possible despite physical changes or shielding, but which may serve the same function
for a person. Below are 2 illustrative examples of functionally equivalent goals from the
BASIL self-help manual.
Functionally equivalent goal, example 1
Sandra decided that she would like to increase her activity levels and said she would have
liked to go to the Age UK exercise group. However, Sandra realised that this will not be
happening due to the need for physical distancing. The BASIL Support Worker advised
that there are exercises online, and she could help Sandra access these. In addition, many
TV channels are showing exercises that can be done at home.
Functionally equivalent goal, example 2
Sandra would like to have a cup of tea with her friend Shirley but realises that this is not
possible. She and Shirley used to meet up on a regular basis, before the ministroke
(TIA), and she really missed their chats. She thought that she might suggest a regular
‘virtual meeting’, rather than just a quick telephone call, if the Support Worker can help
her gain confidence with using her smart phone.
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The primary clinical outcome was self-reported symptoms of depression, assessed by the
PHQ-9 [30]. The PHQ-9 was also administered at screening to ascertain risk of self-harm or
suicide and again at baseline, 1 and 3 months post-randomisation. The primary time point
was 1 month. Other secondary clinical outcomes measured at baseline, 1 and 3 months, were
health-related quality of life (measured by the Short Form (SF)-12v2 mental component
scale (MCS) and physical component scale (PCS)) [31], anxiety (measured by the GAD-7)
[32], perceived social and emotional loneliness (measured by the De Jong Gierveld Scale:
11-item loneliness scale), and questions relating to COVID-19 circumstances and adherence
to government guidelines [33]. The PHQ-9 is scored from 0 to 27, the GAD-7 from 0 to 21,
and the De Jong Gierveld Loneliness Scale from 0 to 11 (emotional subscale from 0 to 6 and
social from 0 to 5), for each a higher score indicates a worse outcome. The physical and men-
tal health component scores of the SF-12v2 range from 0 to 100, where a higher score indi-
cates better health. We also tested our ability to collect resource use data, but these data are
not summarised or described, since there was no planned economic evaluation in this pilot
trial.
Sample size and statistical analysis
Sample size. The primary aim of the BASIL pilot trial was to test the feasibility of the
intervention and the methods of recruitment, randomisation, and follow-up [22]. Sample size
calculations were based on estimating attrition and standard deviation (SD) of the primary
outcome. We aimed to recruit 100 participants. The intervention was delivered by BSWs and
allowed for potential clustering by BSWs assuming an intercluster correlation (ICC) of 0.01
and mean cluster size of 15 based upon previous studies [18]. The effective sample size was
therefore 88. Anticipating 15% to 20% of participants would be lost to follow-up (based on
17% in the CollAborative care and active surveillance for Screen-Positive EldeRs with sub-
threshold depression (CASPER) trial of older adults [18]), this would result in an effective sam-
ple size of at least 70 participants, which is sufficient to allow reasonably robust estimates of
the SD of the primary outcome measure to inform the sample size calculation for a definitive
trial [34,35]. See Statistical Analysis Plan (SAP) in S1 Data.
Statistical analysis. This study is reported as per the Consolidated Standards of Report-
ing Trials (CONSORT) guideline (see S2 Data). The flow of participants through the pilot
trial (number of people identified, approached, screened, eligible, randomised, receiving the
intervention, and providing outcome data) is detailed in a CONSORT flow diagram as per
pilot trial recommendations [Fig 1] [22,36]. The number of individuals withdrawing from
the intervention and/or the trial, and any reasons for withdrawal, was summarised by trial
arm. All baseline and outcome data were summarised descriptively, by trial arm, using
mean and SD for continuous outcomes, and count and percentage for categorical data. To
quantify the acceptability of the intervention, the number and duration of sessions were
summarised.
For each of the clinical outcomes, missing item level data were handled according to the
user guides. No other methods for imputing missing data were employed, which was deemed
appropriate as there were minimal missing data, and this was a pilot trial where all analyses
were purely exploratory. Linear regression was used to explore differences in the clinical out-
comes, adjusting for the baseline measure of the score as a covariate (ANCOVA approach),
between groups at 1 and 3 months. Model assumptions were assessed, and no concerning devi-
ations or observations were observed. The adjusted mean difference (AMD) and 95% confi-
dence interval (CI) was reported as preliminary estimates of effect, but this pilot trial was not
powered to show efficacy. We attach an SAP as a Supporting information (S1 Data).
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Process evaluation
A nested qualitative study was conducted to provide important learning about the study
processes and acceptability of the BASIL intervention. We planned semi-structured inter-
views of up to 15 participants who completed the BASIL intervention (“completers”), up to
10 participants who did not complete the intervention (“non-completers”), and all BSWs
who delivered the intervention (n = 9). Interviews explored views and experiences of the
study and acceptability of the intervention. Initial thematic analysis [37] and subsequent
analysis sensitised by the Theoretical Framework of Acceptability (TFA) [38] were
undertaken.
Fig 1. CONSORT flow diagram.
https://doi.org/10.1371/journal.pmed.1003779.g001
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Patient and public involvement (PPI)
The BASIL trial was informed by a patient and public involvement advisory group (PPI AG)
who were working with the research collective on the existing NIHR-funded research pro-
gramme. This PPI AG included older adults with lived experience of mental health and/or
physical health conditions and caregivers. The PPI AG were consulted on many aspects of the
trial design including modification of the BA intervention for BASIL, remote recruitment of
BASIL participants, and the relevance and readability of study recruitment information. The
group are a vital component of the BASIL trials programme and will continue to contribute
throughout the delivery of this work.
Role of funding source
This project was funded by the NIHR Programme Grants for Applied Research (PGfAR) pro-
gramme (RP-PG-0217-20006). The scope of our preexisting research into multimorbidity in
older people was extended at the outset of the COVID-19 pandemic with the agreement of the
funder to consider loneliness and depression in this vulnerable group. The NIHR PGfAR pro-
gramme had no role in the writing of this manuscript or the decision to submit it for publication.
Ethical approval
Ethical approval for the study was granted by Yorkshire and The Humber—Leeds West
Research Ethics Committee on April 23, 2020, Yorkshire and The Humber—Leeds West
Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS,
UK; +44 (0)207 104 8018; leedswest.rec@hra.nhs.uk), ref: 18/YH/0380 (approved as substantial
amendment 02 under existing NIHR IRAS249030 research programme).
Results
Participant recruitment and characteristics
Database searches were conducted in 2 general practices within Tees, Esk and Wear Valleys
NHS Foundation Trust. A total of 799 study information packs were mailed out across the 2
practices between June 17 and September 4, 2020 (initially in batches of 50, later increased to
100). Of these, 104 were screened for eligibility, and 96 were recruited out of our target of 100:
3 were not eligible as they were currently in receipt of psychological treatment, 2 eligible par-
ticipants did not complete the baseline questionnaire following consent, 1 was no longer inter-
ested in the study, and for 2 more, the reason for nonparticipation was not provided.
Participants were randomised between June 23 and October 15, 2020: 47 to the BA interven-
tion group and 49 to usual care with signposting group (Fig 1).
The mean age of participants was aged 74 years (SD 5.5) and they were mostly White (n = 92,
95.8%), and approximately two-thirds of the sample were female (n = 59, 61.5%) (Table 1). Car-
diovascular conditions (49.0%) and arthritis (38.5%) were the most commonly reported long-
term health conditions. The majority of participants (55.2%) were social/physical distancing and
adhering to UK Government’s guidance in relation to COVID-19 restrictions all of the time
(65.6%). There was reasonable balance in baseline characteristics between the 2 groups, but with
some differences including a larger proportion of females, and current and former smokers, and
fewer participants shielding in the usual care group than the intervention group; however, given
the sample size, each participant per group equates to approximately 2 percentage points, so even
small numerical imbalances equate to more noticeable imbalances in proportions.
Table 2 presents summaries of the clinical outcomes by time point and treatment group.
Unadjusted between-group mean differences tended to favour the intervention.
PLOS MEDICINE The Behavioural Activation in Social Isolation (BASIL) pilot randomised controlled trial
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003779 October 12, 2021 10 / 21







Age, years Mean (SD) 74.1 (5.6) 74.2 (5.4) 74.2 (5.5)
Sex, n (%) Male 17 (34.7) 20 (42.6) 37 (38.5)
Female 32 (65.3) 27 (57.4) 59 (61.5)
Ethnicity, n (%) White 47 (95.9) 45 (95.7) 92 (95.8)
Black or Black British 0 (0.0) 0 (0.0) 0 (0.0)
Asian or Asian British 0 (0.0) 0 (0.0) 0 (0.0)
Other 2 (4.1) 2 (4.3) 4 (4.2)
†LTC type, n (%) Cardiovascular condition 21 (42.9) 26 (55.3) 47 (49.0)
Arthritis 21 (42.9) 16 (34.0) 37 (38.5)
Respiratory condition 17 (34.7) 18 (38.3) 35 (36.5)
Diabetes 14 (28.6) 14 (29.8) 28 (29.2)
Stroke 5 (10.2) 4 (8.5) 9 (9.4)
Chronic pain 2 (4.1) 3 (6.4) 5 (5.2)
Osteoporosis 4 (8.2) 2 (4.3) 6 (6.3)
Neurological condition 1 (2.0) 0 (0.0) 1 (1.0)
Cancer 1 (2.0) 1 (2.1) 2 (2.1)
Other 27 (55.1) 21 (44.7) 48 (50.0)
Smoking status, n (%) I have never smoked 16 (32.7) 22 (46.8) 38 (39.6)
I currently smoke 5 (10.2) 7 (14.9) 12 (12.5)
I am an ex-smoker 28 (57.1) 18 (38.3) 46 (47.9)
Alcohol intake Yes 7 (14.3) 6 (12.8) 13 (13.5)
(3+ units daily), n (%) No 42 (85.7) 41 (87.2) 83 (86.5)
Post-16 education, n (%) Yes 29 (59.2) 32 (68.1) 61 (63.5)
Degree or equivalent, n (%) Yes 18 (36.7) 19 (40.4) 37 (38.5)
Marital status, n (%) Single 1 (2.0) 0 (0.0) 1 (1.0)
Divorced/separated 11 (22.4) 9 (19.1) 20 (20.8)
Widowed 11 (22.4) 10 (21.3) 21 (21.9)
Cohabiting 0 (0.0) 1 (2.1) 1 (1.0)
Civil partnership 0 (0.0) 0 (0.0) 0 (0.0)
Married 26 (53.1) 27 (57.4) 53 (55.2)
Number of children, n (%) 0 3 (6.1) 3 (6.4) 6 (6.3)
1 7 (14.3) 8 (17.0) 15 (15.6)
2 24 (49.0) 16 (34.0) 40 (41.7)
3 10 (20.4) 15 (31.9) 25 (26.0)
4+ 5 (10.2) 5 (10.6) 10 (10.4)
How many people do you share your home with? n (%) Live alone 22 (44.9) 18 (38.3) 40 (41.7)
1 person 26 (53.1) 25 (53.2) 51 (53.1)
2 people 1 (2.0) 3 (6.4) 4 (4.2)
3 people 0 (0.0) 1 (2.1) 1 (1.0)
4 or more people 0 (0.0) 0 (0.0) 0 (0.0)
Current circumstance, n (%) Social/physical distancing 29 (59.2) 24 (51.1) 53 (55.2)
Self-isolating without COVID-19
symptoms
10 (20.4) 4 (8.5) 14 (14.6)
Self-isolating with COVID-19
symptoms
0 (0.0) 0 (0.0) 0 (0.0)
Shielding� 10 (20.4) 19 (40.4) 29 (30.2)
Other 0 (0.0) 0 (0.0) 0 (0.0)
(Continued)
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Engagement with the BASIL intervention
Levels of engagement with the BA intervention were high. Of the 47 intervention participants
randomised to the BA intervention group, 45 (95.7%) commenced the intervention, with 44
participants completing 2 or more sessions. The number of sessions completed range from 0
to 8 (median of 6 sessions) out of a total of up to 8 sessions. Participants preferred telephone
over video contact. Sessions lasted a mean of 36.7 minutes (SD 15.7). Two participants with-
drew from the intervention (after completing 1 and 2 sessions, respectively); one participant
stated their reason for withdrawal was that they felt “well,” and the intervention was “not for
them” as they were already engaging in BA-related activities. At 1 month (the primary clinical
outcome point), the median number of completed sessions for people receiving the BA inter-
vention was 3, and almost all participants were still receiving the BA intervention.
Retention, follow-up, withdrawal, and completeness of data
Of the 96 participants randomised into the study, 90 (93.8%) completed the 1-month follow-
up, and 86 (89.6%) completed the 3-month follow-up. Reasons for withdrawal include per-
sonal reasons, family bereavement, and finding the study/study questions upsetting and anxi-
ety provoking.
Data completeness was good with all patient-reported outcome measures (PHQ-9, GAD-7,
De Jong Gierveld Loneliness Scale, and SF-12v2).
Outcome data and between group comparisons at 1 and 3 months
The adjusted mean difference (AMD) between groups in the PHQ-9 indicated lower severity
in the intervention group at 1 month (−0.50, 95% CI −2.01 to 1.01) and the usual care group at








Adherence to UK Government’s guidance in relation to COVID-19
restrictions, n (%)
All of the time 31 (63.3) 32 (68.1) 63 (65.6)
Most of the time 15 (30.6) 15 (31.9) 30 (31.3)
Some of the time 3 (6.1) 0 (0.0) 3 (3.1)
A little of the time 0 (0.0) 0 (0.0) 0 (0.0)
None of the time 0 (0.0) 0 (0.0) 0 (0.0)
† Conditions are not mutually exclusive so percentages not expected to sum to 100.
� Shielding was self-defined as following government guidance on shielding due to being a clinically highly vulnerable category. The definitions and list of categories
changed according to shifting guidance during the course of the study.
Other conditions include (all listed for a single person unless otherwise indicated in brackets, but people may have listed more than one other condition): USUAL CARE
—underactive thyroid/other thyroid problem (n = 5), high blood pressure (n = 4), high cholesterol (n = 2), sciatica (n = 2), depression (n = 2), non-chronic pain in in
back and legs, “tablets for bones,” autonomic neuropathic dysfunction (mainly affects bowels), brain tumour, Crohn disease, deaf in one ear from birth, flat feet,
spondylitis in the spine, anxiety, kidney problems, previous stroke (n = 2), previous history of cancer, nerve problems in back, hernia in lumbar disc, Barrett disease,
emphysema, sleep apnea, kidney infections/sepsis, anemia, digestive problems, pacemaker in stomach, angina, ileostomy from ulcerative colitis, glaucoma in one eye,
right total hip replacement due to arthritis, raised cholesterol, some cardiovascular disease—short of breath on exertion, retinitis pigmentosa (eye sight), Reynaud
syndrome, skin condition, lichen sclerosus, skin lupus; INTERVENTION—underactive thyroid or other thyroid issue (n = 7), high blood pressure (n = 3), depression
(n = 3), previous cancer (n = 2), atrial fibrillation, angina (n = 2), premature ventricular contractions, emphysema, joint pain, lung function issues due to asbestos
exposure, sciatica, mild bronchiectasis, eczema, IBS, Sturge–Weber syndrome, vertigo, tinnitus, chronic kidney disease, polymyalgia, high cholesterol, kidney cyst, and
gall stones.
COVID-19, Coronavirus Disease 2019; IBS, irritable bowel syndrome; LTC, long-term condition; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1003779.t001
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Table 2. Patient-reported outcome measures.
Outcome measure Control Intervention
PHQ-9, n, mean (SD)
Baseline 49, 7.5 (6.2) 47, 6 (5.6)
1 month 45, 6.3 (5.9) 45, 4.9 (4.6)
3 months 44, 5.7 (5.3) 42, 5.3 (5.4)
PHQ-9 categories baseline, n (%)
Minimal depression (0 to 4) 22 (44.9) 21 (44.7)
Mild depression (5 to 9) 10 (20.4) 14 (29.8)
Moderate depression (10 to 14) 11 (22.4) 9 (19.1)
Moderately severe depression (15 to 19) 3 (6.1) 1 (2.1)
Severe depression (20 to 27) 3 (6.1) 2 (4.3)
PHQ-9 categories 1 month, n (%)
Minimal depression (0 to 4) 22 (48.9) 24 (53.3)
Mild depression (5 to 9) 12 (26.7) 12 (26.7)
Moderate depression (10 to 14) 6 (13.3) 8 (17.8)
Moderately severe depression (15 to 19) 3 (6.7) 1 (2.2)
Severe depression (20 to 27) 2 (4.4) 0 (0.0)
PHQ-9 categories 3 months, n (%)
Minimal depression (0 to 4) 21 (47.7) 23 (54.8)
Mild depression (5 to 9) 15 (34.1) 11 (26.2)
Moderate depression (10 to 14) 4 (9.1) 4 (9.5)
Moderately severe depression (15 to 19) 3 (6.8) 4 (9.5)
Severe depression (20 to 27) 1 (2.3) 0 (0.0)
GAD-7, n, mean (SD)
Baseline 49, 5.2 (5.8) 47, 3.8 (4.8)
1 month 45, 4.2 (5.1) 45, 3.6 (4.2)
3 months 44, 3.7 (5.0) 42, 3.5 (3.9)
GAD-7 categories baseline, n (%)
Anxiety (0 to 4) 31 (63.3) 35 (74.5)
Mild anxiety (5 to 9) 9 (18.4) 7 (14.9)
Moderate anxiety (10 to 14) 4 (8.2) 3 (6.4)
Severe anxiety (15 to 21) 5 (10.2) 2 (4.3)
GAD-7 categories 1 month, n (%)
Anxiety (0 to 4) 31 (68.9) 30 (66.7)
Mild anxiety (5 to 9) 8 (17.8) 10 (22.2)
Moderate anxiety (10 to 14) 3 (6.7) 4 (8.9)
Severe anxiety (15 to 21) 3 (6.7) 1 (2.2)
GAD-7 categories 3 months, n (%)
Anxiety (0 to 4) 31 (70.5) 28 (66.7)
Mild anxiety (5 to 9) 9 (20.5) 9 (21.4)
Moderate anxiety (10 to 14) 1 (2.3) 4 (9.5)
Severe anxiety (15 to 21) 3 (6.8) 1 (2.4)
De Jong Gierveld Loneliness Scale, n, mean (SD)
Baseline 49, 5.1 (3.2) 47, 4.6 (3.5)
1 month 45, 4.6 (3.1) 45, 4.7 (3.0)
3 months 44, 5.0 (3.0) 42, 4.1 (2.9)
De Jong Gierveld Emotional Loneliness Subscale, n, mean (SD)
Baseline 49, 3.1 (1.9) 47, 3.0 (2.0)
(Continued)
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lower severity in the usual care group at 1 month (0.28, 95% CI −0.51 to 1.06) and the interven-
tion group at 3 months (−0.87, 95% CI −1.56 to −0.18) when the 95% CI did not contain 0
(Table 3).
Process evaluation and changes to the intervention in light of participant
feedback
Intervention participants were invited to be interviewed following completion of the 1-month
follow-up and conclusion of their participation in the BASIL pilot intervention. Semi-struc-
tured interviews were conducted with 15 participants who completed the BA intervention. A
study participant who did not complete the BASIL intervention was interviewed as a “non-
completer.” All 9 BSWs who delivered the BASIL intervention were interviewed between
August 2020 and November 2020. All interviews were conducted over the telephone, digitally
recorded with consent and transcribed verbatim. Transcripts formed the basis for analysis. We
summarise the key findings from a thematic analysis [37] and subsequent changes to the
BASIL intervention ahead of the BASIL main trial. Analysis sensitised by the TFA [38] will be
reported separately. Intervention participant and BSW demographics are reported in S1 and
S2 Tables. Two researchers (CCG and CS) undertook the qualitative data analysis, coding tran-
scripts, and reviewing/developing a coding frame.
Recruitment and study eligibility. Study recruitment methods appeared to be generally
acceptable and clear:
“The doctor gives you a warning that this is about to happen [be contacted] and then you’re
prepared when somebody phones up that it’s not a scam, a con, which is what I don’t worry
about it because I know how to deal with it but to some people it could be worrying.”
(OA16)
Table 2. (Continued)
Outcome measure Control Intervention
1 month 45, 3.0 (1.7) 45, 3.1 (1.9)
3 months 44, 3.4 (1.7) 42, 3.0 (1.7)
De Jong Gierveld Social Loneliness Subscale, n, mean (SD)
Baseline 49, 2.0 (1.8) 47, 1.6 (1.8)
1 month 45, 1.5 (1.8 45, 1.6 (1.8)
3 months 44, 1.6 (1.8) 42, 1.1 (1.6)
SF-12v2 (physical component score), n, mean (SD)
Baseline 49, 39.4 (10.7) 47, 40.3 (11.3)
1 month 45, 40.0 (10.5) 45, 41.4 (12.4)
3 months 44, 41.0 (11.5) 42, 41.8 (11.7)
SF-12v2 (mental component score), n, mean (SD)
Baseline 49, 47.0 (13.9) 47, 48.9 (10.5)
1 month 45, 48.4 (13.0) 45, 52.0 (9.5)
3 months 44, 49.0 (11.5) 42, 51.1 (9.7)
Range of possible scores: PHQ-9 0 to 27; GAD-7 0 to 21; and De Jong Gierveld total 0 to 11—emotional subscale 0 to
6, social subscale 0 to 5 (higher indicates worse outcome). SF-12v2 subscales 0 to 100 (higher indicates better
outcome).
GAD-7, Generalised Anxiety Disorder 7; PHQ-9, Patient Health Questionnaire 9; SD, standard deviation; SF, Short
Form.
https://doi.org/10.1371/journal.pmed.1003779.t002
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Some participants, generally participants without symptoms of depression at study entry
and also some BSWs, raised the importance of more targeted recruitment to the BASIL
intervention:
“I do think just some consideration needs to be given to who we’re targeting, maybe it’s not
quite so useful for people on the threshold of depression and feel that they’re doing quite
well.” (BSW 04)
“I think possibly it needs to be more targeted, so anybody who has a painful medical condi-
tion or who lives alone who is isolated. Certainly I think it would benefit [people who are
isolated] a lot. I think the wide spread that you have currently can be more targeted. [it
could be] more focused and more helpful.” (OA02)
Intervention delivery and content. Remote delivery of the intervention by telephone was
acceptable. Although video calls were offered, these were not taken up by participants. Some
participants and BSWs reported they would have preferred face-to-face intervention delivery,
had this been possible. One participant suggested that those with hearing difficulties would
find telephone delivery more difficult. The number and frequency of intervention sessions
were acceptable, although one participant reported that they would prefer 1 session per week
to allow them time to implement agreed activities and plans. Some BSWs reported that it
could be difficult to stick to the 30-minute timing for more complex or isolated cases, where
meetings took longer.
The BASIL BA self-help booklet was thought to be engaging, and people found the mood/
behaviour cycle understandable. However, some participants—those with few depression
Table 3. Unadjusted and AMD between groups at 1 and 3 months for primary and secondary outcomes measure.
Unadjusted mean difference (95% CI) AMDa (95% CI)
1 month
PHQ-9 −1.44 (−3.66, 0.77) −0.50 (−2.01, 1.01)
GAD-7 −0.54 (−2.52, 1.44) 0.20 (−1.33, 1.73)
De Jong Gierveld Scale (total) 0.13 (−1.14, 1.41) 0.28 (−0.51, 1.06)
De Jong Gierveld Emotional Loneliness Subscale 0.07 (−0.68, 0.81) 0.14 (−0.39, 0.67)
De Jong Gierveld Social Loneliness Subscale 0.07 (−0.68, 0.81) 0.14 (−0.42, 0.69)
SF-12v2 (physical component score)b 1.40 (−3.42, 6.22) 0.34 (−4.17, 4.85)
SF-12v2 (mental component score)b 3.60 (−1.17, 8.37) 1.91 (−2.64, 5.15)
3 months
PHQ-9 −0.39 (−2.70, 1.91) 0.19 (−1.36, 1.75)
GAD-7 −0.16 (−2.09, 1.78) 0.31 (−1.08, 1.70)
De Jong Gierveld Scale (total) −0.86 (−2.14, 0.43) −0.87 (−1.56, −0.18)
De Jong Gierveld Emotional Loneliness Subscale −0.36 (−1.09, 0.36) −0.37 (−0.85, 0.11)
De Jong Gierveld Social Loneliness Subscale −0.50 (−1.22, −0.23) −0.50 (−1.00, −0.01)
SF-12v2 (physical component score)b 0.81 (−4.16, 5.77) 0.11 (−4.46, 4.67)
SF-12v2 (mental component score) b 2.09 (−2.48, 6.65) 1.26 (−2.64, 5.15)
a Adjusted for baseline measure of the outcome as a covariate.
b For the SF12, a positive score indicates direction of effect in favour of in intervention group, and a negative score
indicates direction of effect in favour of control group.
AMD, adjusted mean difference; CI, confidence interval; GAD-7, Generalised Anxiety Disorder 7; PHQ-9, Patient
Health Questionnaire 9.
https://doi.org/10.1371/journal.pmed.1003779.t003
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symptoms at study entry—found this model of limited relevance. Several participants reported
that they would use the booklet after the intervention ended:
“So, in days of darkness I’ll be able to flick through it [the booklet] and say, that’s what that
was all about, how to break things down and not get upset about them and not let them get
you down.” (OA06)
The patient stories in the booklet were reported to be relevant, although some participants
reported that booklet activity examples could ideally be more varied. Both BSWs and partici-
pants found activity planning to be sometimes difficult, especially where some services were
shut under lockdown conditions. Planned activities may therefore need to be sufficiently flexi-
ble to accommodate changes in COVID-19 restrictions.
Study adaptations. The process evaluation led to intervention adaptations for the BASIL
main trial, including refining the study eligibility criteria, adaptions to the self-help booklet to
make reference to a wider range of example activities, making reference to modifying goals,
bringing discussion of “functional activities” forward, and providing a large print version of
the self-help booklet when needed.
Discussion
The BASIL trial is an external pilot trial designed to test acceptability of an adapted intervention
and to refine trial procedures and design prior to undertaking a full-scale trial [22,39]. Our
main finding is that higher-risk older people with LTCs living under COVID-19 restrictions
were receptive to an approach to participate in a trial of a behavioural intervention. When
offered BA, they preferred telephone contact rather than an offer of technology-enabled video
calling. Levels of engagement with BA were high, with a greater proportion completing 6 or
more planned sessions. Some people with LTCs declined the BASIL offer of telephone support.
In qualitative interviews, it was clear that those with very mild depression and good adapta-
tion to socially-isolating restrictions were not an appropriate target group. This has led us to
refine and target our intervention in a fully powered trial, and we will now only focus on older
people who have some depressive symptoms above a threshold and at risk of further deteriora-
tion in mental health.
Although underpowered to test effectiveness, the between-group comparisons using CIs
included benefit for BA in mitigating levels of depression at 3 months. For our measure of
loneliness, there was good evidence of benefit and was unlikely to be a chance finding. Our
preliminary analysis is in line with a CI approach to the interpretation of pilot trials [40], and
we are keen not to overinterpret the positive finding of mitigating loneliness using BA. How-
ever, this is an encouraging finding that triangulates with the theoretical basis of BA in social
isolation and the evidence of engagement and feasibility in the pilot trial. This justifies the
need for a full-scale trial [41], where the consistency of this effect will be tested with greater lev-
els of power and precision. The BASIL+ trial (the fully powered follow-on trial) is now under-
way and is preregistered (https://doi.org/10.1186/ISRCTN63034289) to reflect the design
adaptations from the pilot study.
The BASIL trial and nested qualitative work adds to an emerging literature on the use of
psychological interventions that incorporate cognitive or behavioural strategies to address
loneliness and its causal role in depression [42]. Research to date has shown behavioural
approaches to be highly effective in the treatment of depression among older people
[18,20,43,44], and the preliminary results of the BASIL trial lend support to this approach in
the face of COVID-19 restrictions and in mitigating loneliness [41]. A fully powered trial of
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BA is now underway, and in time, this will report on the short- and long-term clinical and
cost-effectiveness of a scalable behavioural psychosocial intervention. This will add to an
emerging trial-based literature to establish the clinical and cost-effectiveness of interventions
that target loneliness [12,45].
Our pilot trial was also undertaken rapidly and during the COVID-19 pandemic in early
2020. As such, we, along with other researchers undertaking trials during COVID-19, have had
to adapt the methods used to generate randomised evidence. We have shown that it is possible
to deliver trials with adaptations to minimise patient contact and streamline recruitment proce-
dures. This makes us confident that this is an efficient method of participant engagement and
follow-up for future trials, both under COVID-19 and beyond the pandemic [46]. It is of note
that the time elapsed between the onset of the pandemic and the recruitment of the first partici-
pant was less than 3 months. We chose to study the impact of a plausible psychosocial interven-
tion to mitigate depression and loneliness in an at-risk population of older people with
multimorbidity. Population surveys under COVID-19 have shown that younger people are also
at risk of loneliness [47] and psychological deterioration [48]. It is important that interventions
to tackle the higher rates of depression and loneliness in all age groups are also developed and
evaluated. Finally, we note that we worked with experts by experience at all stages of the design
and delivery of the BASIL trial, and we believe the high levels of engagement reflect the positive
contribution made by older people with lived experience in the BASIL programme.
The BASIL study had 2 main limitations. First, we found that the intervention was still
being delivered at the prespecified primary outcome point, and this fed into the design of the
main trial where a primary outcome of 3 months is now collected. Second, this was a pilot trial
and was not designed to test between group differences with high levels of statistical power.
Type 2 errors are likely to have occurred, and a larger trial is now underway to test for robust
effects and replicate signals of effectiveness in important secondary outcomes such as loneli-
ness. Finally, we acknowledge that we have relied on self-reported activity and social contact,
and we ultimately do not know if this did in fact increase as a consequence of the intervention.
The BASIL trial remains in follow-up, and we will report 12-month outcomes when these
become available.
At the outset of the COVID-19 pandemic, it was predicted that there would be significant
impacts on public mental health [5], including loneliness and depression, as a consequence of
pandemic restrictions. This has come to pass [48], and population surveys indicate increased
reports of loneliness and reports of depression [2]. The pandemic has also prompted a number
of studies to understand the impacts of COVID-19 [49], but there have been very few studies
to evaluate psychosocial interventions to mitigate psychological impact [46]. To our knowl-
edge, BASIL is the first study to report trial-based evidence.
A clinical priority and policy imperative is to identify a brief and scalable intervention to
prevent and mitigate loneliness, particularly in older people [50,51]. The preliminary results
are in line with potential benefit for this intervention in mitigating loneliness at 3 months. We
will now test the short- and long-term clinical and cost-effectiveness. This evidence may prove
to be useful in improving the mental health of populations during the time of COVID-19 and
also in mitigating depression and loneliness in socially isolated at-risk populations after the
pandemic has passed [15].
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